Cerebrolysin

Cerebrolysin is a peptide mixture purified from pig-brain proteins, given by injection and studied in dozens of human trials for stroke, dementia and brain-injury recovery. Cerebrolysin is an approved prescription drug in many countries but not in the US, and independent reviews call the benefit promising but not yet proven. Here’s the honest picture.

What is cerebrolysin?

Cerebrolysin is not a single peptide — cerebrolysin is a mixture. It’s made by breaking down purified pig-brain proteins with enzymes into a standardized soup of small peptides and free amino acids, then bottling that as a liquid for injection. That makes it the odd one out on this site: most compounds here are one defined molecule with one formula, while cerebrolysin is a biological preparation, closer to a processed extract than to a lab-synthesized drug. It has been sold as a prescription medicine (originally coded FPF-1070) since the 1950s and is used today across Russia, China, and parts of Europe and Asia — but the FDA has never approved it.

How does cerebrolysin work?

Cerebrolysin is thought to work by imitating the brain’s own repair signals. The brain keeps a set of proteins called neurotrophic factors — think of them as the support crew that keeps neurons alive, helps them sprout new connections, and shields them when an injury or stroke floods the area with damage. The small peptides in cerebrolysin are proposed to behave a bit like those factors, nudging neurons to survive and rewire. Picture watering a lawn after a drought rather than laying fresh sod: the idea is to help the cells you still have recover, not to grow a new brain. That’s the mechanism story, and it’s a reasonable one — but most of the direct evidence for it comes from animal and cell studies (indexed research, PubMed), and exactly how cerebrolysin acts in a living human brain hasn’t been pinned down.

What does the research show?

Here’s what sets cerebrolysin apart from almost every other “nootropic peptide”: it actually has human trials — dozens of randomized ones. The catch is that the results are mixed, and a lot of the flattering data comes from studies tied to the manufacturer. In ischaemic stroke, some randomized trials and pooled analyses report better recovery scores, but an independent Cochrane systematic review of the randomized evidence found no clear effect on death or long-term dependence and rated the trials low-to-moderate quality (Cochrane reviews). In vascular dementia, randomized trials — including one that used a 20 mL/day IV course (NCT00947531) — have shown short-term cognitive gains, which Cochrane again judged possible but low-certainty. In traumatic brain injury, the multi-site CAPTAIN program (NCT01606111) and others reported functional-outcome trends without settling the question. The forward-looking part: independent trials keep launching — a Phase 2 study in the genetic small-vessel disease CADASIL (NCT05755997) and a stroke-consciousness trial (NCT04427241) are among those still active — so the evidence base is being tested right now, not gathering dust. The detailed per-use grades are in the evidence section below.

What the community reports (the “nootropic” use)

The single most important honesty point on this page: cerebrolysin’s human trials are in patients — stroke, dementia, brain injury — not in healthy people chasing sharper focus. The online nootropic crowd uses cerebrolysin off-label for memory, mood and “brain fog,” typically in daily IM or subcutaneous shots over 10-to-20-day courses, sometimes repeated a few times a year. Those are personal reports, not studies: no control group, no blinding, and a heavy dose of survivorship bias (people who feel nothing tend to stop posting). They’re useful for understanding why cerebrolysin is popular, not for proving it does anything in a healthy brain — where, honestly, no controlled trial has looked.

Is cerebrolysin safe? Side effects

Cerebrolysin has a fairly reassuring short-term safety record in trials, but that record has real limits. The most common complaints are mild: burning or warmth at the injection site, dizziness, headache, and a flushed feeling — many of which track with infusing it too fast. Some patients report agitation, restlessness or trouble sleeping, and rare allergic reactions have been described. Two honest caveats matter more than the side-effect list. First, product labeling in countries where cerebrolysin is approved cautions against use in severe epilepsy and severe kidney impairment, and in known allergy. Second, essentially all of this safety data is short-term and in supervised patients; there is no long-term safety evidence for a healthy person self-injecting it as a nootropic, and because it’s a pig-derived biological product, source purity and sterility depend entirely on the maker.

FDA & legal status (2026)

Cerebrolysin is not FDA-approved and is not a legal dietary supplement in the United States — so there’s no US-sanctioned way to use it. It is, however, an approved prescription drug in roughly 40-plus other countries, which is why US buyers usually import it for personal use rather than buy a domestic “research chemical” powder. Cerebrolysin isn’t a scheduled or controlled substance, so simple possession isn’t the legal flashpoint that importing an unapproved injectable can be. The dated, jurisdiction-by-jurisdiction breakdown — plus the openFDA corroboration that no approved US product exists — is in the regulatory block below. Treat any status claim as dated and re-check it.

How is cerebrolysin used, and can it be mixed?

Cerebrolysin ships differently from most peptides on this site: it comes as a ready-to-use liquid in glass ampoules, so there’s no freeze-dried powder to reconstitute and no reconstitution math to do. In the trials, doses were given by IV infusion — commonly in the range of about 10 to 30 mL per day, over treatment courses of roughly 10 to 20 days (registered studies, ClinicalTrials.gov); smaller volumes are given intramuscularly. Those are doses reported in cited studies for medical use, not a protocol — there’s no validated dose for healthy cognitive enhancement. On mixing: because cerebrolysin is a complex peptide-and- amino-acid solution, combining it in one syringe with other compounds is a stability unknown, and our mixing compatibility reference covers where the honest answer is “not enough data.”

How cerebrolysin compares to other nootropic peptides

Cerebrolysin’s real edge over its shelf-mates is the sheer volume of human data — most brain peptides in the nootropic hub have far thinner records. It sits near other neuroprotection-minded compounds like ARA-290, an EPO-derived peptide studied for nerve and tissue protection, and the CNS-active tesofensine; the throughline is “help the nervous system cope,” not “build muscle.” What cerebrolysin shares with the rest of the peptide catalog is the gap between enthusiasm and proof — it just happens to have more trials arguing about that gap than almost anything else here.

Frequently asked questions

Does cerebrolysin actually work?

For its studied medical uses, the honest answer is “maybe, and it depends who you ask.” Dozens of randomized trials exist for stroke, dementia and brain injury, and some report benefit — but independent Cochrane reviews rated the evidence low-to-moderate quality and found no clear effect for stroke, and much of the positive data is manufacturer-linked. For healthy “nootropic” use, there’s no controlled evidence at all.

Is cerebrolysin legal in the US?

Cerebrolysin is not FDA-approved and not a dietary supplement, so it can’t be sold for medical use in the United States. It isn’t a scheduled/controlled substance, but importing an unapproved injectable drug is a legal gray area. It is an approved prescription medicine in many other countries.

How do people take cerebrolysin?

Cerebrolysin comes as a ready-to-use liquid in ampoules and is given by injection — IV infusion in the trials (about 10 to 30 mL/day over 10-to-20-day courses), or intramuscularly in smaller volumes. There’s no reconstitution step because it’s not a powder.

Is cerebrolysin banned in sport?

Cerebrolysin is not specifically named on the WADA Prohibited List, so we mark it “not established” rather than a flat yes or no. Because it’s a neuroactive peptide preparation, any athlete under anti-doping rules should confirm its status with their own authority before using it — categories like peptide hormones and growth factors are worth checking against.

Is cerebrolysin the same as a “nootropic” like a racetam?

No. Racetams are small synthetic molecules taken orally; cerebrolysin is an injectable biological mixture of peptides derived from pig brain, developed as a neurorecovery drug for stroke and dementia rather than as a study aid. They share a reputation online, not a mechanism or an evidence base.

Who is cerebrolysin for — and who should be cautious?

Cerebrolysin draws in two very different people: patients (or families) dealing with stroke, dementia or brain-injury recovery who’ve seen it used abroad, and healthy biohackers hoping to sharpen cognition. The honest framing splits them apart. For the first group, cerebrolysin has more human trial data than nearly any peptide on this site — a real point in its favor — but independent reviewers still call the benefit unproven, and it’s an unapproved import in the US. For the second group, there simply isn’t controlled evidence that cerebrolysin does anything in a healthy brain, and the long-term safety of self-injecting a pig-derived biologic is unknown. Anyone with epilepsy, significant kidney disease, a known allergy, or an unwillingness to accept real unknowns has every reason to wait for stronger, independent data — which, encouragingly, is still being gathered.